(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 11.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Immunocore Holdings's revenue in 2024 is $264,253,750.On average, 7 Wall Street analysts forecast IMCR's revenue for 2024 to be $15,315,405,412, with the lowest IMCR revenue forecast at $14,604,890,468, and the highest IMCR revenue forecast at $16,598,853,359. On average, 7 Wall Street analysts forecast IMCR's revenue for 2025 to be $16,628,860,325, with the lowest IMCR revenue forecast at $15,147,616,460, and the highest IMCR revenue forecast at $19,679,568,535.
In 2026, IMCR is forecast to generate $18,444,881,907 in revenue, with the lowest revenue forecast at $15,521,103,164 and the highest revenue forecast at $27,736,438,906.